<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04038996</url>
  </required_header>
  <id_info>
    <org_study_id>SNP_irAE</org_study_id>
    <nct_id>NCT04038996</nct_id>
  </id_info>
  <brief_title>The Role of SNP rs2910164 in Patients Treated With Immune Checkpoint Inhibitors</brief_title>
  <official_title>A Single-Center, Prospective, Observational Trial to Analyze the Relationship Between Single Nucleotide Polymorphism rs2910164 and the Efficacy and Safety of Immune Checkpoint Inhibitor Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Freiburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Freiburg</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to investigate whether the SNP rs2910164 in the pre-miR-146a
      gene is associated with outcome and toxicity of immune checkpoint inhibitor therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The single nucleotide polymorphism (SNP) rs2910164 within the gene for microRNA-146a
      (miR-146a) reduces miR-146a expression. Previous studies of the investigators demonstrated
      that this SNP was associated with increased acute GvHD severity in patients undergoing
      allogeneic hematopoietic stem cell transplantation. In this prospective, observational study
      the investigators aim to analyze, whether SNP rs2910164 is associated with severity of
      immune-related adverse events of immune checkpoint inhibitor therapy. Moreover, association
      of rs2910164 with outcome parameters will be studied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">February 2020</completion_date>
  <primary_completion_date type="Actual">February 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Severity of immune-related adverse events (irAEs)</measure>
    <time_frame>2 years</time_frame>
    <description>according to CTCAE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The rs2910164 genotype will be assessed using DNA isolated from peripheral blood samples and
      Taqman realtime PCR assays.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with cancer undergoing immune checkpoint inhibitor therapy
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmed diagnosis of cancer

          -  treatment with an immune checkpoint inhibitor (anti-PD-1, anti-PD-L1 or anti-CTLA4)

          -  age ≥ 18 years

          -  peripheral blood sample available

          -  written informed consent

          -  ability to understand the nature of the study and the study related procedures and to
             comply with them

        Exclusion Criteria:

          -  age &lt; 18 years

          -  lack of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Zeiser, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Freiburg</affiliation>
  </overall_official>
  <reference>
    <citation>Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2008 May 20;105(20):7269-74. doi: 10.1073/pnas.0802682105. Epub 2008 May 12.</citation>
    <PMID>18474871</PMID>
  </reference>
  <reference>
    <citation>Stickel N, Hanke K, Marschner D, Prinz G, Köhler M, Melchinger W, Pfeifer D, Schmitt-Graeff A, Brummer T, Heine A, Brossart P, Wolf D, von Bubnoff N, Finke J, Duyster J, Ferrara J, Salzer U, Zeiser R. MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation. Leukemia. 2017 Dec;31(12):2732-2741. doi: 10.1038/leu.2017.137. Epub 2017 May 9.</citation>
    <PMID>28484267</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 28, 2019</study_first_submitted>
  <study_first_submitted_qc>July 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Freiburg</investigator_affiliation>
    <investigator_full_name>Robert Zeiser</investigator_full_name>
    <investigator_title>Head of Department of Tumorimunnology and Immunoregulation</investigator_title>
  </responsible_party>
  <keyword>immune checkpoint inhibitor</keyword>
  <keyword>single nucleotide polymorphism</keyword>
  <keyword>microRNA</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

